Candidemia After Solid Organ Transplant tied to High Mortality Risk: JAMA
A recent study published in the Journal of the American Medical Association showed that although candidemia is a relatively rare complication following solid organ transplantation, but it is associated with a significantly high mortality risk. This population-based cohort study highlighted the serious outcomes of this infection in transplant recipients, which emphasized the need for vigilance despite its low incidence.
This research analyzed health data from over 10,000 adult solid organ transplant recipients (SOTRs) across Ontario from 2011 to 2022, with follow-up extending through the end of 2023. The study explored to better understand how often candidemia occurs in this vulnerable population and how it impacts survival.
Out of 10,249 transplant recipients, candidemia was identified in 135 patients which represents a relatively low overall incidence. Within one year of transplantation, the probability of infection stood at 0.87%, which rose to 1.67% over a 10-year period. Despite the low incidence, the consequences were severe.
The most common fungal species responsible was Candida albicans, followed by Candida glabrata and Candida parapsilosis. These infections can enter the bloodstream, often in patients with weakened immune systems like the individuals taking immunosuppressive drugs after receiving a transplant.
Among different transplant types, the lung recipients underwent the highest risk. Their 10-year cumulative probability of developing candidemia reached 4.17%, significantly higher than other groups. Also, this research observed that infections appeared earlier in patients with thoracic (chest-area) transplants, with a median onset of just over a month, when compared to nearly 6 months in abdominal transplant recipients.
Nearly 40% of patients with candidemia died within 30 days, and that figure rose to 47.4% within 90 days. Statistical analysis revealed that developing candidemia increased the risk of death nearly 7-fold when compared to transplant patients without the infection.
Both drug-susceptible and drug-resistant fungal strains were associated with significantly higher mortality. The patients infected with fluconazole-resistant strains faced the highest risk, which showed the growing challenge of antifungal resistance in clinical care.
Overall, the findings emphasize the need for better prevention, early detection, and targeted treatment strategies, especially for high-risk groups like lung transplant recipients. Future studies and trails are needed to identify the patients who are most vulnerable and how interventions can be implemented sooner.
Source:
Bitterman, R., Kus, J. V., Verma, G., Kopp, A., Husain, S., Kwong, J. C., & Hosseini-Moghaddam, S. M. (2026). Incidence and outcomes of Candida bloodstream infection in solid organ transplant recipients. JAMA Network Open, 9(3), e261467. https://doi.org/10.1001/jamanetworkopen.2026.1467
